Hospital Torrecárdenas, Almería, Spain.
Vaccine. 2011 Aug 11;29(35):6042-8. doi: 10.1016/j.vaccine.2011.06.026. Epub 2011 Jun 23.
Two randomized trials of 13-valent pneumococcal conjugate vaccine (PCV13) relative to PCV7 evaluated the immune responses of coadministered antigens comprising Infanrix(®) hexa/Infanrix(®)-IPV+Hib (diphtheria, tetanus, 3-component acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b). After the 3-dose infant series, immunogenic noninferiority was demonstrated for all concomitantly administered antigens between the PCV13 and PCV7 groups. All antigens elicited good booster responses after the toddler dose except pertussis toxoid; however, 99.6% subjects achieved pertussis toxoid protective antibody level ≥5EU/mL in both groups. These results support the concomitant administration of PCV13 and Infanrix hexa/Infanrix-IPV+Hib as part of routine immunization schedules.
两项针对 13 价肺炎球菌结合疫苗(PCV13)与 PCV7 的随机试验评估了同时接种的抗原(包括 Infanrix®hexa/Infanrix®-IPV+Hib[白喉、破伤风、无细胞百日咳、乙型肝炎、灭活脊髓灰质炎病毒和流感嗜血杆菌 b 型])的免疫反应。在婴儿的 3 剂系列疫苗接种后,PCV13 组与 PCV7 组之间所有同时接种的抗原均显示出非劣效免疫原性。除百日咳类毒素外,所有抗原在幼儿剂量后均产生良好的加强反应;然而,两组中 99.6%的受试者均达到了百日咳类毒素保护性抗体水平≥5EU/mL。这些结果支持将 PCV13 与 Infanrix hexa/Infanrix-IPV+Hib 同时接种作为常规免疫接种计划的一部分。